Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects
Autore:
Sakai, T; Aoyama, N; Kita, T; Sakaeda, T; Nishiguchi, K; Nishitora, Y; Hohda, T; Sirasaka, D; Tamura, T; Tanigawara, Y; Kasuga, M; Okumura, K;
Indirizzi:
Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ Kobe Hyogo Japan 6500017 m, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ Kobe Hyogo Japan 6500017 2, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ, Sch Med, Dept Endoscopy, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ Kobe Hyogo Japan 6500017 y, Chuo Ku, Kobe, Hyogo 6500017, Japan
Titolo Testata:
PHARMACEUTICAL RESEARCH
fascicolo: 6, volume: 18, anno: 2001,
pagine: 721 - 727
SICI:
0724-8741(200106)18:6<721:CGAPOT>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
S-MEPHENYTOIN 4'-HYDROXYLATION; HELICOBACTER-PYLORI INFECTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; OMEPRAZOLE METABOLISM; OXIDATIVE-METABOLISM; POOR METABOLIZERS; PEPTIC-ULCER; LANSOPRAZOLE; AMOXICILLIN; DISPOSITION;
Keywords:
CYP2C19 genotype; pharmacokinetics; proton pump inhibitor; omeprazole; lansoprazole; rabeprazole;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Okumura, K Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan Kobe Univ Kobe Hyogo Japan 6500017 Kobe, Hyogo 6500017, Japan
Citazione:
T. Sakai et al., "CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects", PHARM RES, 18(6), 2001, pp. 721-727

Abstract

Purpose. To predict the CYP2C19 genotype-dependence in anti-Helicobacter pylori (H. pylori) therapy when lansoprazole or rabeprazole was used insteadof omeprazole as a proton pump inhibitor (PPI). Methods. A comparative pharmacokinetic study with each PPI was designed asan open, randomized, and crossover study of 18 Japanese healthy volunteerswho were classified into the homozygous, heterozygous extensive metabolizer and the poor metabolizer based on the CYP2C19 genotype determined by PCR-RFLP method. Each subject received a single oral dose of 20 mg omeprazole, 30 mg lansoprazole, or 20 mg sodium rabeprazole, with at least 1 week washout period between treatments. Plasma concentrations of PPIs and their metabolites were monitored until 12 h after medication. Results. Pharmacokinetic profiles of omeprazole and lansoprazole were wellcorrelated with the CYP2C19 genotype. The heterozygous extensive metabolizer was slightly different from the homozygote, but there was no statistically significant difference. The CYP2C19 genotype dependence found for lansoprazole was not obvious compared with omeprazole. As for rabeprazole, the pharmacokinetic profile was independent of the CYP2C19 genotype. Conclusions. CYP2C19 genotype dependence will be found in the anti-H. pylori therapy even when lansoprazole is used as the PPI.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 15:44:36